A Phase 2 interventional study of Evolocumab and Standard of care in Hypercholesterolemia, sponsored by Amgen. Completed at 187 sites in 18 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-21.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 6th largest by enrollment, is one of 4 that started in 2011, is one of 5 in phase 2, and was the 4th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,324 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 6th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2011, is one of 5 in phase 2, and was the 4th registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary clinical hypothesis is that long-term exposure of evolocumab (AMG 145) will be safe and well tolerated in adults with hypercholesterolemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 52 participants began treatment with evolocumab 420 mg once a month (QM) for 4 years during the all-investigational product \[all-IP\] period.
Biological: Evolocumab · Other: Standard of care
Participants received evolocumab 420 mg once a month plus standard of care for the first year of the study (SOC-controlled period). At week 52 participants continued treatment with evolocumab 420 mg QM for another 4 years during the all-IP period.
Biological: Evolocumab
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
Number of Participants With Adverse Events
Adverse event (AE) severity assessments were made using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading, version 4.03, where grade 1 = mild AE, grade 2 = moderate AE, Grade 3 = severe AE, grade 4 = life-threatening AE and Grade 5 = death due to AE.
Time frame: 52 weeks in the SOC-controlled period and up to 4 years in the All-IP period; actual median duration of treatment in the All-IP period was 46.9 months.
Low-density Lipoprotein Cholesterol (LDL-C) Level at Week 24 and Week 52
Time frame: Baseline of parent study and extension study weeks 24 and 52
Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Level at Week 24 and Week 52
Time frame: Baseline of parent study and extension study weeks 24 and 52
Apolipoprotein B Level at Week 24 and Week 52
Time frame: Baseline of parent study and extension study weeks 24 and 52
Total Cholesterol/HDL-C Ratio at Week 24 and Week 52
Time frame: Baseline of parent study and extension study weeks 24 and 52
Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24 and Week 52
Time frame: Baseline of parent study and extension study weeks 24 and 52
This extension study was conducted at 188 centers in 18 countries. Participants were enrolled from one of five eligible phase 2 parent studies: 20101154 (NCT01375777), 20101155 (NCT01380730), 20090158 (NCT01375751), 20090159 (NCT01375764), and 20110231 (NCT01652703). Participants were enrolled from October 2011 to June 2013.
| Milestone | Standard of Care | Evolocumab + SOC |
|---|---|---|
| Started | 442 | 882 |
| Received evolocumab | 0 | 881 |
| Completed | 398 | 822 |
| Not completed | 44 | 60 |
| Withdrew: Withdrawal by subject | 24 | 38 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Lost to follow-up | 10 | 5 |
| Withdrew: Other | 8 | 13 |
| Withdrew: Reason missing | 0 | 2 |
| Milestone | Standard of Care | Evolocumab + SOC |
|---|---|---|
| Started | 398 | 822 |
| Received evolocumab | 374 | 777 |
| Completed | 328 | 682 |
| Not completed | 70 | 140 |
| Withdrew: Lost to follow-up | 21 | 30 |
| Withdrew: Withdrawal by subject | 30 | 66 |
| Withdrew: Death | 3 | 13 |
| Withdrew: Sponsor decision | 1 | 0 |
| Withdrew: Other | 14 | 31 |
| Withdrew: Reason missing | 1 | 0 |
Adverse event (AE) severity assessments were made using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading, version 4.03, where grade 1 = mild AE, grade 2 = moderate AE, Grade 3 = severe AE, grade 4 = life-threatening AE and Grade 5 = death due to AE.
| Participants | SOC-controlled Period: Standard of Care | SOC-controlled Period: Evolocumab + SOC | All-IP Period: SOC / Evolocumab + SOC | All-IP Period: Evolocumab + SOC / Evolocumab + SOC |
|---|---|---|---|---|
| All adverse events | 327 | 728 | 342 | 718 |
| Adverse events ≥ grade 3 | 46 | 99 | 111 | 229 |
| Adverse events ≥ grade 4 | 2 | 11 | 8 | 28 |
| Serious adverse events | 30 | 72 | 76 | 172 |
| AEs leading to discontinuation of evolocumab | 0 | 28 | 16 | 27 |
| Fatal adverse events | 0 | 0 | 1 | 3 |
| mg/dL | Standard of Care | Evolocumab + SOC | Control in Parent Study: SOC | Control in Parent Study: Evolocumab + SOC | Evolocumab in Parent Study: SOC | Evolocumab in Parent Study: Evolocumab + SOC |
|---|---|---|---|---|---|---|
| Parent Study Baseline | 144.6 ± 37.4 | 139.7 ± 36.7 | 147.7 ± 34.3 | 139.5 ± 33.6 | 143.4 ± 38.5 | 139.8 ± 37.8 |
| Week 24 | 136.9 ± 41.5 | 64.1 ± 33.3 | 142.5 ± 44.7 | 63.9 ± 34.6 | 134.8 ± 40.2 | 64.2 ± 32.9 |
| Week 52 | 140.5 ± 40.0 | 65.0 ± 34.4 | 143.1 ± 39.8 | 64.1 ± 33.2 | 139.4 ± 40.1 | 65.3 ± 34.9 |
| mg/dL | Standard of Care | Evolocumab + SOC | Control in Parent Study: SOC | Control in Parent Study: Evolocumab + SOC | Evolocumab in Parent Study: SOC | Evolocumab in Parent Study: Evolocumab + SOC |
|---|---|---|---|---|---|---|
| Parent Study Baseline | 170.7 ± 43.0 | 165.1 ± 40.9 | 173.8 ± 39.6 | 165.5 ± 38.9 | 169.6 ± 44.2 | 165.0 ± 41.7 |
| Week 24 | 161.4 ± 45.5 | 84.3 ± 37.7 | 166.9 ± 47.5 | 84.3 ± 39.0 | 159.4 ± 44.6 | 84.3 ± 37.3 |
| Week 52 | 164.9 ± 44.5 | 85.3 ± 39.0 | 168.8 ± 45.3 | 85.0 ± 38.4 | 163.4 ± 44.1 | 85.4 ± 39.2 |
| mg/dL | Standard of Care | Evolocumab + SOC | Control in Parent Study: SOC | Control in Parent Study: Evolocumab + SOC | Evolocumab in Parent Study: SOC | Evolocumab in Parent Study: Evolocumab + SOC |
|---|---|---|---|---|---|---|
| Parent Study Baseline | 113.2 ± 25.3 | 110.4 ± 23.8 | 115.4 ± 23.1 | 110.3 ± 22.4 | 112.4 ± 26.0 | 110.4 ± 24.3 |
| Week 24 | 107.9 ± 26.3 | 60.8 ± 23.3 | 110.5 ± 27.0 | 60.7 ± 23.9 | 106.9 ± 26.0 | 60.9 ± 23.1 |
| Week 52 | 109.5 ± 26.8 | 61.6 ± 23.5 | 110.7 ± 26.3 | 61.7 ± 23.0 | 109.1 ± 27.0 | 61.6 ± 23.7 |
| ratio | Standard of Care | Evolocumab + SOC | Control in Parent Study: SOC | Control in Parent Study: Evolocumab + SOC | Evolocumab in Parent Study: SOC | Evolocumab in Parent Study: Evolocumab + SOC |
|---|---|---|---|---|---|---|
| Parent Study Baseline | 4.516 ± 1.617 | 4.386 ± 1.393 | 4.458 ± 1.345 | 4.388 ± 1.340 | 4.538 ± 1.708 | 4.386 ± 1.413 |
| Week 24 | 4.198 ± 1.536 | 2.603 ± 0.978 | 4.192 ± 1.408 | 2.594 ± 0.970 | 4.201 ± 1.584 | 2.607 ± 0.982 |
| Week 52 | 4.277 ± 1.652 | 2.626 ± 1.025 | 4.252 ± 1.434 | 2.622 ± 1.033 | 4.286 ± 1.733 | 2.628 ± 1.023 |
| ratio | Standard of Care | Evolocumab + SOC | Control in Parent Study: SOC | Control in Parent Study: Evolocumab + SOC | Evolocumab in Parent Study: SOC | Evolocumab in Parent Study: Evolocumab + SOC |
|---|---|---|---|---|---|---|
| Parent Study Baseline | 0.759 ± 0.237 | 0.739 ± 0.217 | 0.764 ± 0.201 | 0.735 ± 0.212 | 0.757 ± 0.249 | 0.741 ± 0.218 |
| Week 24 | 0.717 ± 0.242 | 0.386 ± 0.178 | 0.715 ± 0.222 | 0.385 ± 0.183 | 0.718 ± 0.250 | 0.387 ± 0.176 |
| Week 52 | 0.726 ± 0.256 | 0.394 ± 0.185 | 0.719 ± 0.216 | 0.393 ± 0.186 | 0.729 ± 0.271 | 0.394 ± 0.185 |
Collected over 52 weeks in the SOC-controlled period and up to 4 years in the All-IP period; median duration of treatment in the All-IP period was 46.9 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOC-controlled Period: SOC | 2/442 (0.5%) | 30/442 (6.8%) | 217/442 (49.1%) |
| SOC-controlled Period: Evolocumab + SOC | 1/882 (0.1%) | 72/882 (8.2%) | 513/882 (58.2%) |
| All-IP Period: SOC / Evolocumab | 3/398 (0.8%) | 78/398 (19.6%) | 311/398 (78.1%) |
| All-IP Period: Evolocumab + SOC / Evolocumab | 13/822 (1.6%) | 181/822 (22%) | 626/822 (76.2%) |
| All-IP Period: Total | 16/1,220 (1.3%) | 259/1,220 (21.2%) | 937/1,220 (76.8%) |
| Event | SOC-controlled Period: SOC | SOC-controlled Period: Evolocumab + SOC | All-IP Period: SOC / Evolocumab | All-IP Period: Evolocumab + SOC / Evolocumab | All-IP Period: Total |
|---|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/442 | 3/882 | 5/398 | 9/822 | 14/1220 |
| Angina pectorisCardiac disorders | 2/442 | 4/882 | 1/398 | 9/822 | 10/1220 |
| Atrial fibrillationCardiac disorders | 1/442 | 1/882 | 2/398 | 7/822 | 9/1220 |
| Non-cardiac chest painGeneral disorders | 1/442 | 4/882 | 0/398 | 7/822 | 7/1220 |
| Chest painGeneral disorders | 1/442 | 4/882 | 1/398 | 6/822 | 7/1220 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/442 | 0/882 | 1/398 | 5/822 | 6/1220 |
| AppendicitisInfections and infestations | 1/442 | 5/882 | 2/398 | 3/822 | 5/1220 |
| Coronary artery diseaseCardiac disorders | 0/442 | 1/882 | 2/398 | 4/822 | 6/1220 |
| CataractEye disorders | 0/442 | 0/882 | 2/398 | 2/822 | 4/1220 |
| Inguinal herniaGastrointestinal disorders | 1/442 | 0/882 | 2/398 | 0/822 | 2/1220 |
| Event | SOC-controlled Period: SOC | SOC-controlled Period: Evolocumab + SOC | All-IP Period: SOC / Evolocumab | All-IP Period: Evolocumab + SOC / Evolocumab | All-IP Period: Total |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 64/442 | 148/882 | 122/398 | 236/822 | 358/1220 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 18/442 | 59/882 | 63/398 | 109/822 | 172/1220 |
| Upper respiratory tract infectionInfections and infestations | 29/442 | 72/882 | 57/398 | 118/822 | 175/1220 |
| Back painMusculoskeletal and connective tissue disorders | 22/442 | 62/882 | 51/398 | 117/822 | 168/1220 |
| HypertensionVascular disorders | 20/442 | 52/882 | 40/398 | 99/822 | 139/1220 |
| InfluenzaInfections and infestations | 24/442 | 57/882 | 47/398 | 81/822 | 128/1220 |
| BronchitisInfections and infestations | 17/442 | 48/882 | 40/398 | 94/822 | 134/1220 |
| CoughRespiratory, thoracic and mediastinal disorders | 19/442 | 41/882 | 40/398 | 77/822 | 117/1220 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 14/442 | 44/882 | 32/398 | 70/822 | 102/1220 |
| DiarrhoeaGastrointestinal disorders | 11/442 | 41/882 | 33/398 | 61/822 | 94/1220 |
The full analysis set included all randomized participants
| Age, Continuous(years) | Standard of Care | Evolocumab + SOC | Total |
|---|---|---|---|
| Mean | 57.6 ± 11.5 | 56.9 ± 11.6 | 57.1 ± 11.6 |
| Age, Customized(Participants) | Standard of Care | Evolocumab + SOC | Total |
|---|---|---|---|
| < 65 years | 307 | 632 | 939 |
| ≥ 65 years | 135 | 250 | 385 |
| Sex: Female, Male(Participants) | Standard of Care | Evolocumab + SOC | Total |
|---|---|---|---|
| Female | 241 | 459 | 700 |
| Male | 201 | 423 | 624 |
| Ethnicity (NIH/OMB)(Participants) | Standard of Care | Evolocumab + SOC | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 39 | 52 |
| Not Hispanic or Latino | 429 | 843 | 1272 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Standard of Care | Evolocumab + SOC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 4 |
| Asian | 87 | 168 | 255 |
| Black or African American | 24 | 54 | 78 |
| Native Hawaiian or Other Pacific Islander | 2 | 5 | 7 |
| White | 325 | 648 | 973 |
| Other | 1 | 4 | 5 |
| Mixed Race | 0 | 2 | 2 |
| Region(Participants) | Standard of Care | Evolocumab + SOC | Total |
|---|---|---|---|
| North America | 214 | 441 | 655 |
| Europe | 133 | 261 | 394 |
| Asia Pacific | 95 | 180 | 275 |
| Parent Study Baseline Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL) | Standard of Care | Evolocumab + SOC | Total |
|---|---|---|---|
| Mean | 144.6 ± 37.4 | 139.7 ± 36.7 | 141.3 ± 37.0 |
| Stratification Factor: Parent Study Treatment Assignment(Participants) | Standard of Care | Evolocumab + SOC | Total |
|---|---|---|---|
| Evolocumab once monthly (QM) | 193 | 387 | 580 |
| Evolocumab every 2 weeks (Q2M) | 129 | 256 | 385 |
| No evolocumab | 120 | 239 | 359 |
Showing the first 100 of 187 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2011 to primary completion in Jun 2018, 80 months.
Results were first posted in Jul 2019, 1 year after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 80 months is above that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab